

HIGH TB BURDEN | HIGH HIV BURDEN

Estimates of TB burden^a 2012

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	9.2 (3.8–17)	14 (5.8–25)
Mortality (HIV+TB only)	2.2 (1.9–2.8)	3.3 (2.9–4.2)
Prevalence (includes HIV+TB)	110 (47–190)	159 (71–282)
Incidence (includes HIV+TB)	80 (66–95)	119 (98–142)
Incidence (HIV+TB only)	12 (10–14)	18 (15–22)
Case detection, all forms (%)	76 (64–92)	

TB case notifications 2012

NEW CASES (%)	RETREATMENT CASES (%)
Smear-positive 30 998 (54)	Relapse 1 887 (68)
Smear-negative 17 537 (31)	Treatment after failure 327 (12)
Smear-unknown / not done	Treatment after default 577 (21)
Extrapulmonary 8 852 (15)	Other
Other	
Total new 57 387	Total retreatment 2 791
Other (history unknown) 1 030	
Total new and relapse 59 274	Total cases notified 61 208

New cases

	SMEAR-POSITIVE	SMEAR-NEGATIVE/ UNKNOWN/ NOT DONE	EXTRAPULMONARY
M:F ratio	2.4		
Age < 15	117		

Laboratories

Smear (per 100 000 population)	1.6
Culture (per 5 million population)	4.9
Drug susceptibility testing (per 5 million population)	1.3
Is second-line drug susceptibility testing available?	Yes, in country

Treatment success rate 2011 (%)

New smear-positive and/or culture-positive	85
New smear-negative/extrapulmonary	78
Retreatment	69
Is rifampicin used throughout treatment for new patients?	Yes

TB/HIV 2012

	NUMBER	(%)
TB patients with known HIV status	44 035	(72)
HIV-positive TB patients	5 807	(13)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	4 460	(77)
HIV-positive TB patients on antiretroviral therapy (ART)	3 591	(62)
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

Estimates of MDR-TB burden 2012^a

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.7 (1–2.6)	35 (28–42)
MDR-TB cases among notified pulmonary TB cases	800 (480–1 200)	960 (780–1 200)

Reported cases of MDR-TB 2012

	NEW	RETREATMENT	TOTAL
Cases tested for MDR-TB			7 379
Laboratory-confirmed MDR-TB cases			492
Patients started on MDR-TB treatment			

Financing TB control

National TB programme budget (US\$ millions)	44 ^b
% Funded domestically	92%
% Funded internationally	2%
% Unfunded	6%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

^a Ranges represent uncertainty intervals.

^b Based on data reported for 2013 in the 2012 round of data collection. In 2013, Thailand was not able to report funding for the sub-national level.

